Neuroinflammatory and Other Disorders
Multiple Sclerosis Clinical Trial Experience
Even though there are now many approved multiple sclerosis (MS) treatments, patients still have significant unmet needs. Within this complex, competitive landscape, customers often struggle to position and differentiate their compounds to engage sites and patients. With 51 trials conducted in the past five years, our MS team members and neurologists not only know how to navigate these trials, but they also understand how to favorably position your compound, considering a nuanced understanding of competitive strengths and weaknesses such as side effect profiles and routes of administration.
Within the neuroinflammatory group, we also have experience in a range of rare diseases such as neuromyelitis optica and chronic inflammatory demyelinating polyneuropathy, where we combine our therapeutic expertise with our rare disease acumen.
Clinical Studies for Pain Disorders and Migraine
More than half of all studies in pain indications fail because the outcomes do not distinguish placebo from active drug responses. We have developed a robust process for placebo response mitigation that helps produce more precise data outcomes using operational controls, which subsequently helps form a better picture of placebo versus drug response.
Our relationships with experienced clinical trial investigators result in quicker study startups. In addition, our use of a variety of clinical technologies – electronic data collection, electronic case report forms and handheld diaries, interactive voice response and interactive web response – allows for rapid retrieval and analysis of data for a single country or global studies. We have also developed streamlined processes to integrate multiple systems to minimize data duplication and ease the burden on sites and subjects for data entry.
Our experience includes acute pain, chronic pain, neuropathic pain and migraine pain.
Parkinson’s disease and other Movement Disorders Research
PPD has conducted full-service movement disorder trials, including gene therapy studies. Our experts in movement disorders recognize the tremendous advancements and momentum in this therapeutic area. We have global movement disorder experience across all phases of drug development in a broad spectrum of populations, including gene mutation populations.